Technologies

Invention
This invention describes new inhibitors of the protease activated receptor 2 (PAR2), a G protein coupled receptor (GPCR) involved in inflammatory related diseases, for the treatment of asthma and a wide range of other diseases.

Background
It is estimated that by 2025 400 million people will be suffering from asthma. While the prevalence of asthma is increasing, treatments for asthma have remained constant over the past several decades. These treatments provide control for only approximately half of asthma patients. There needs to be drugs developed that allow patients to have more control over their asthma.